Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 4-((4-bromophenyl)-(ethoxyimino)methyl)-1'-((2,4-dimethyl-3-pyridinyl)carbonyl)-4'-methyl-1,4'-bipiperidine N-oxide
2. Sch 351125
3. Sch-351125
4. Sch351125
1. Chembl336672
2. Sch-351125
3. [4-[4-[(e)-c-(4-bromophenyl)-n-ethoxycarbonimidoyl]piperidin-1-yl]-4-methylpiperidin-1-yl]-(2,4-dimethyl-1-oxidopyridin-1-ium-3-yl)methanone
4. Schering C
5. [3h]ancriviroc
6. Gtpl802
7. Gtpl804
8. Schembl2939135
9. Chebi:177442
10. [3h]sch-351125
11. [3h]sch 351125
12. L000937
13. Q27074462
14. 3-[(4-{4-[(1z)-(4-bromophenyl)(ethoxyimino)methyl]piperidin-1-yl}-4-methylpiperidin-1-yl)carbonyl]-2,4-dimethylpyridin-1-ium-1-olate
| Molecular Weight | 557.5 g/mol |
|---|---|
| Molecular Formula | C28H37BrN4O3 |
| XLogP3 | 4.3 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 6 |
| Exact Mass | 556.20490 g/mol |
| Monoisotopic Mass | 556.20490 g/mol |
| Topological Polar Surface Area | 70.6 Ų |
| Heavy Atom Count | 36 |
| Formal Charge | 0 |
| Complexity | 756 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
CCR5 Receptor Antagonists
Compounds and drugs that inhibit or block the activity of CCR5 RECEPTORS. (See all compounds classified as CCR5 Receptor Antagonists.)
INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
A Ancriviroc manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ancriviroc, including repackagers and relabelers. The FDA regulates Ancriviroc manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ancriviroc API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Ancriviroc supplier is an individual or a company that provides Ancriviroc active pharmaceutical ingredient (API) or Ancriviroc finished formulations upon request. The Ancriviroc suppliers may include Ancriviroc API manufacturers, exporters, distributors and traders.
Ancriviroc Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ancriviroc GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ancriviroc GMP manufacturer or Ancriviroc GMP API supplier for your needs.
A Ancriviroc CoA (Certificate of Analysis) is a formal document that attests to Ancriviroc's compliance with Ancriviroc specifications and serves as a tool for batch-level quality control.
Ancriviroc CoA mostly includes findings from lab analyses of a specific batch. For each Ancriviroc CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ancriviroc may be tested according to a variety of international standards, such as European Pharmacopoeia (Ancriviroc EP), Ancriviroc JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ancriviroc USP).
LOOKING FOR A SUPPLIER?
